Company intelligence
Beacon
Beacon is the essential decision-support tool for developers of complex therapeutics.
About Beacon
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape. With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.
Verified activity
Signals from Beacon
6 published signals
Research & Knowledge
Beacon published Part 1 of its H1 2026 Autoimmune Landscape Review highlighting trends and highlights of the autoimmune pipeline.
Reported by Beacon
Research & Knowledge
Beacon team gathered insights from the Oligonucleotide for CNS Summit, with Victoria Marshall presenting a review of the mRNA-based drug development landscape covering preclinical and clinical pipeline, recent commercial developments, and future therapies and trends.
Reported by Beacon
Research & Knowledge
Beacon published Part 2 of its H1 2026 Cell Therapy Landscape Review, which uncovers key commercial milestones and emerging technologies defining the field.
Reported by Beacon
Research & Knowledge
Beacon released Parts 1 and 2 of the H1 2026 ADC Landscape Review to download for ADC drug, commercial, clinical trial, and regulatory analysis.
Reported by Beacon
Research & Knowledge
Beacon Consulting's time in clinical development analysis reveals that new wave ADCs spend approximately 17 months less in clinical development compared to their predecessors.
Reported by Beacon
Presence & Recognition
Beacon is hosting an upcoming webinar examining key preclinical and clinical programmes, recent partnerships and investments, emerging therapies, and market trends on 10 September at 4 PM BST.
Reported by Beacon